Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling
Velasco R, Shao C, Cutler B, Strunck J, Kent G, Cassidy P, Choate K, Greiling T. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology 2024, 160: 641-645. PMID: 38598229, PMCID: PMC11007649, DOI: 10.1001/jamadermatol.2024.0257.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexPityriasis rubra pilarisDermatology Life Quality Index scoresInvolvement of interleukinsQuality Index scoreFood and Drug Administration-approved treatmentPrimary outcomeUS Food and Drug Administration-approved treatmentPsoriasis area severity index scoreSex-matched healthy controlsIL-23p19 inhibitorsP19 subunit of IL-23Index scoreArea Severity IndexIL-23/IL-17Subunit of IL-23Per-protocol analysisClinical responseStudy drugDosing scheduleClinical respondersClinical improvementMale patientsIL-23GuselkumabBiologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply